“…Therefore, we consider this complementary strategy, which includes useage of both CDC and ELISA techniques, simultaneously or alternatively, as appropriate and useful for HLA antibody screening in all pretransplant patients, since it provides the advantages of both of techniques, in conjunction. Our data are in agreement with other reports [18,[23][24][25], that also confirmed the higher sensitivity and greater ability to detect antibodies by ELISA technique in comparison to CDC. This discrepancy of positive test results obtained only by ELISA 121 (19.96%), in comparisom to the positive results obtained only by CDC test 64 (10.56%), could be explained by either a greater sensitivity of the ELISA or to the presence of noncytotoxic antibodies which CDC method could not detect.…”